

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Zaltrap (ziv-aflibercept)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Zaltrap (ziv-aflibercept)

APPROVAL CRITERIA

Requests for Zaltrap (ziv-aflibercept) may be approved if the following criteria are met:

- I. The individual has a diagnosis of metastatic colon, rectal, colorectal, appendiceal, or anal adenocarcinoma (Label, NCCN 2A); **AND**
- II. The individual is resistant to or has disease progression following treatment with an oxaliplatin-containing regimen; **AND**
- III. Zaltrap (ziv-aflibercept) will be used in combination with an irinotecan based regimen; **AND**
- IV. Zaltrap (ziv-aflibercept) will be given in a single line of therapy.

Requests for Zaltrap (ziv-aflibercept) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Ziv-aflibercept is given concomitantly with cetuximab, panitumumab, or bevacizumab (or bevacizumab biosimilar); **OR**
- III. Ziv-aflibercept is used in combination with the same irinotecan-based regimen that was previously used in combination with bevacizumab (or bevacizumab biosimilar).

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 22, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499-3506.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

6. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. *Eur J Cancer*. 2014; 50(2):320-331.
7. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on April 25, 2019.
 - a. Colon Cancer. V1.2020. Revised December 19, 2019.
 - b. Rectal Cancer. V1.2020. Revised December 19, 2019.
 - c. Anal Carcinoma. V1.2020. Revised November 19, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.